Zyprexa regulatory briefing

We anticipate differential labeling (re: risk for hyperglycemia, treatment emergent diabetes and related metabolic issues) with our next submission:

- Expect label change in the Precaution section at a minimum, more likely as a warning
- Even FDA attempts to “class-label” could take 6-12 months to implement with other products
- Analyst community has indicated that this could be a trigger for Lilly disinvestment

There is substantial risk in opening the Zyprexa label to a public Advisory Committee discussion; that risk is not new and has been previously communicated internally.

The position of the Zyprexa Product Team is that private negotiations (in advance of a submission) provide the opportunity to better influence the outcome, and that the timing of any outcome should be considered in the context of corporate performance (e.g. manufacturing issues, new product launches, etc.)

Recommendation:

Contributors:
Regulatory          Brophy, Stotka
Investor Relations  Harford
LillyUSA            Robinson, Parkin, Jordan
ZPT                 Breier, Cavazzoni, Bruno, Bandick